ArticleEmerging infectious diseases2015
Multidrug-resistant tuberculosis in Europe, 2010-2011.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.Respiration; international review of thoracic diseases · 2024Guideline
- HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Linezolid for drug-resistant pulmonary tuberculosis.The Cochrane database of systematic reviews · 2019Pooled it
- Explainable prediction of MDR/RR-TB in tuberculosis-diabetes mellitus multimorbidity: a machine learning model developed and validated in a dual-center study.BMC infectious diseases · 2026Article
- Trends in Antituberculosis Drug Resistance and Associated Factors: A 31-Year Observational Study at a Tertiary Hospital in Barcelona.Antibiotics (Basel, Switzerland) · 2025Article
- Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus.Frontiers in medicine · 2025Article
- Effects of mutations in multiple Ethionamide-resistance-associated genes amongFrontiers in cellular and infection microbiology · 2025Article
- Risk factors for multidrug-resistant tuberculosis: a predictive model study.Frontiers in medicine · 2024Article
- Designing molecular diagnostics for current tuberculosis drug regimens.Emerging microbes & infections · 2023Article
- Sociodemographic and Clinical Factors Associated with Treatment Outcomes for Drug-resistant Tuberculosis.The American journal of tropical medicine and hygiene · 2022Article
- Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Contribution of Governance and Socioeconomic Factors to theAntibiotics (Basel, Switzerland) · 2022Article
- Whole genome analysis of extensively drug resistant Mycobacterium tuberculosis strains in Peru.Scientific reports · 2021Article
- Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2020Article
- Using Bayesian spatial models to map and to identify geographical hotspots of multidrug-resistant tuberculosis in Portugal between 2000 and 2016.Scientific reports · 2020Article
- Multidrug-resistant Mycobacterium tuberculosis: a report of cosmopolitan microbial migration and an analysis of best management practices.BMC infectious diseases · 2020Article
- Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study.BMC infectious diseases · 2020Article
- Multidrug-resistant tuberculosis in the United States, 2011-2016: patient characteristics and risk factors.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020Article
- A nationwide study of multidrug-resistant tuberculosis in Portugal 2014-2017 using epidemiological and molecular clustering analyses.BMC infectious diseases · 2019Article
- Surveillance of drug resistance tuberculosis based on reference laboratory data in Ethiopia.Infectious diseases of poverty · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to ≥1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.